OpenAI introduces GPT-Rosalind for life-sciences research; working with Amgen (AMGN), Moderna (MRNA), Thermo Fisher (TMO) and others
Use Cases & Partnerships
- Scientists can use new life sciences research plugin for Codex, available today in GitHub.
- Working with customers like Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific & others to apply GPT-Rosalind across workflows.
Context
OpenAI's introduction of GPT-Rosalind marks a significant step in leveraging AI for life sciences research, collaborating with key industry players such as Amgen and Moderna. This development could enhance R&D efficiencies in biotechnology and pharmaceuticals, but the broader implications for equity markets and investment appetite in these sectors may take time to unfold as analysts assess the tangible impact on productivity and innovation.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#AMGEN INC#AMGN.US#MICROSOFT CORP#MSFT.US#THERMO FISHER SCIENTIFIC INC#TMO.US#SOFTWARE#RICHARD FISHER#ECONOMIC COMMENTARY#IMPORTANT#FIXED INCOME#EQUITIES#US SESSION#CENTRAL BANK#BIOTECHNOLOGY#LIFE SCIENCES TOOLS & SERVICES#SYSTEMS SOFTWARE#BIOTECHNOLOGY (GROUP)#LIFE SCIENCES TOOLS & SERVICES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#AMGN#MODERNA INC#MRNA#TMO#OPEN AI#US EQUITIES